PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Revenue of PolyPeptide Group AG (PPGN.SW)
Revenue in 2023 (TTM): $370.34 M
According to PolyPeptide Group AG's latest financial reports the company's current revenue (TTM) is $370.34 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of PolyPeptide Group AG
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $370.34 M | $5.37 M | $-25,606,175 | $-67,327,907 | $-59,463,756 |
| 2022 | $324.81 M | $60.1 M | $38.21 M | $8.75 M | $8.98 M |
| 2021 | $326.13 M | $115.25 M | $96.47 M | $69.18 M | $54.63 M |
| 2020 | $259.28 M | $84.6 M | $67.55 M | $43.56 M | $36.22 M |
| 2019 | $234.22 M | $82.74 M | $57.11 M | $34.95 M | $29.75 M |
| 2018 | $207.58 M | $71.81 M | $49.23 M | $34.05 M | $27.54 M |